– Vida’s diabetes management program
achieves lasting results for participants. Because chronic conditions like diabetes,
obesity, and hypertension often occur simultaneously, Vida’s unique program was
built from the ground up to treat multiple conditions at the same time.
– The new partnership, which will launch in
January of 2021, allows eligible individuals access to Vida’s group diabetes
coaching, in-app peer group support, digital therapeutics for diabetes and
co-occurring chronic conditions, and more to help them manage their diabetes
and their whole health.
– Kentucky has the seventh highest prevalence of diabetes of any state with 13.7% of the
adult population reporting having the disease, well above the U.S. average of
10.9%. The percent of Kentuckians with diabetes has more than doubled since
2000 when only 6.5% of the population reported having been diagnosed.
Additionally, about two thirds of adult Kentuckians are considered overweight or obese
which increases the risk of Type II Diabetes among other chronic illnesses.
– The mobile-first experience is uniquely
personalized to each user through a combination of provider expertise and
machine learning algorithms that utilize data from 100+ app and device
integrations, as well as biometric data, and more to personalize the program
and content. The program addresses the root causes behind an individual’s
diabetes, and, using the power of human connection, psychology, and nutritional
expertise, Vida drives long-term behaviors that shift the course of the
– Clinical trials technology company Medidata has
acquired the digital biomarker business of MC10.
– MC10’s offerings will bring novel clinical analytics
and biosensor capabilities to Medidata’s existing technology solutions,
enhancing Medidata’s capabilities to integrate data from wearable sensors –
including clinical grade metrics – in clinical trials.
– With this acquisition, Medidata’s integrated offering
will help provide life sciences companies and device developers with greater
understanding of diseases, transformational therapies, and novel endpoints.
a Dassault Systèmes company, the global leader in creating end-to-end solutions
to support the entire clinical development process, acquired
the digital biomarker business of MC10. MC10’s offerings will bring novel
clinical analytics and biosensor capabilities to Medidata’s existing Patient Cloud solutions
in ePRO (patient-reported outcomes), eCOA (clinical outcome assessments), and
biomarker discovery. This will enhance Medidata’s capabilities of integrating data from wearable
sensors – including clinical grade metrics – to help
customers successfully virtualize clinical trials.
MC10 is a Lexington, MA-based privately held
company focused on improving human health through digital solutions. The
company combines conformal BioStamp sensors with clinical analytics to unlock
novel insights from physiological data collected from the home or in clinical
settings. The company flagship product, BioStamp nPoint, is intended for the
clinical research community.
Why It Matters
Remote, patient-centered technologies have become
an essential part of clinical research, especially in the age of COVID-19; the
physical restrictions placed on patients and clinical sites caused by the
pandemic can interfere with launching a clinical study and carrying it to
completion. Wearable sensors are used in about 15 percent of studies, and the
use of sensors is expected to grow to approximately 70 percent by 2025.*
Medidata leads the industry in building and integrating new technologies to revolutionize clinical research in pursuit of patient-centric therapy development. MC10’s focus on clinical-grade data capture and novel digital biomarker development represents an important next chapter – advancing the understanding of disease progression and treatment effect in the home.
“Medidata is excited to add the pioneering work at MC10 to our ongoing efforts in building a new platform for ingestion and analytics across a wide array of mobile sensors,” said Anthony Costello, senior vice president, Mobile Health, Medidata. “Incorporating remote biometric data capture and analysis that includes the MC10 nPoint Biostamp, alongside other leading mobile devices, will further strengthen the Medidata platform and help propel the digital transformation of life sciences.”
Acquisition Builds Integrated Offering
An integrated Medidata offering will provide research companies and device developers new and innovative ways to collect, normalize, and analyze data in pursuit of new therapy development. This enhanced capability will also create a closer connection between patients and the ecosystem of trailblazing researchers, practitioners, and life science companies committed to deepening a shared understanding of the disease, transformational therapies, and novel endpoints.
“Medidata is an exceptional fit for MC10. Our combined expertise will help customers and partners take a more data-driven approach to bringing targeted therapies to patients,” said Ben Schlatka, co-founder and CEO, MC10. “We are looking forward to moving ahead together, accelerating the development and deployment of new innovative offerings for our customers and ultimately transforming therapy development to improve the lives of patients.”
– Imprivata launches a new palm vein scanner solution: Imprivata PatientSecure to power touchless biometric patient identification for healthcare.
– The next generation palm scanner, developed in
collaboration with Keyo, will help healthcare organizations solve the challenge
of patient ID amidst the COVID-19 pandemic by eliminating the need to touch any
surfaces. (It’s also a core component of the Imprivata digital identity
framework for healthcare, which provides a unified, security strategy for
managing identities across devices and locations.)
Imprivata, the digital identity company for healthcare, has unveiled its next-generation touchless biometric patient identification solution, delivered through a combination of a next-generation palm scanner with an antimicrobial copper coating, sensor, and software. The touchless solution is the result of a collaboration between Imprivata and Keyo, whose joint expertise in biometric identification, rapid innovation, and user-centric design produced this latest advancement in digital identity management for patients. The solution enables healthcare organizations to ensure clinicians have access to patients’ correct medical records while giving patients confidence in the safety of their medical care and the security of their medical information.
PatientSecure Palm Vein Scanner for Touchless Biometric
Imprivata PatientSecure helps solve the challenges
of patient identity for the nation’s largest and most complex healthcare
organizations by combining the best of modern patient matching technologies –
namely biometric and referential matching – to securely and accurately match
patients to their medical records using a process of in-person identity
proofing, advanced record resolution, and authentication. Imprivata PatientSecure
is a core component of the Imprivata digital
identity framework for healthcare, a unified, security- and efficiency-focused strategy for managing
identities across the complex healthcare ecosystem.
Why Palm Vein Biometrics?
Palm vein biometrics are less intrusive than other biometric
technologies and among the most accurate. With touchless authentication,
patient risk of infection is also reduced. Palm vein scanning can be used in
any workflow but is the only biometric that can be used for non-responsive
patient identification. The solution can also be taken mobile on WOWs and
tablets for bedside registration and other points of care.
In addition to being touchless, the scanner features an
antimicrobial copper coating, which kills 99.9% of bacteria*. So, aside from
routine hygiene practices, such as hand washing and disinfecting, copper adds
another layer of hygiene to surfaces by continuously killing harmful bacteria
and microbes. In addition, the scanners are easy to clean, fast, and intuitive
Why It Matters
With the outbreak of COVID-19, both patients and provider organizations experienced heightened awareness and concern about the risk of transmission from frequently touched surfaces. Working together, Imprivata and Keyo addressed this challenge head-on, to bring the next generation of advanced biometric identity technology to healthcare institutions. By elevating Imprivata PatientSecure to a touchless solution, Imprivata ensures positive patient identification while limiting risks of transmission.
– With its touchless patient identification solution, Imprivata PatientSecure helps healthcare organizations achieve the following goals:
– Improve patient safety and reduce medical errors;
– Enhance patient experience and streamline workflows with touchless authentication;
– Protect against fraud and eliminate duplicate and overlaid medical records; and
– Reduce medical claim denials and improve financial outcomes.
“Patients are expecting a safe and streamlined experience as they return to physical locations for medical care amidst the COVID-19 pandemic,” said Dr. Sean Kelly, Chief Medical Officer at Imprivata. “We’re pleased to help our customers meet those expectations with the touchless biometric identification, improved patient matching, and workflow optimization offered with the latest version of Imprivata PatientSecure.”
Healthcare providers are seeing between 50 and 175 times (1) more patients via telehealth than before. Telehealth platforms* offer solutions for a wide array of different healthcare issues. An estimated 20 percent of all emergency room visits and 24 percent of routine office visits and outpatient volume could be delivered virtually via telehealth.
Telehealth is a win-win for providers and patients. It both increases the availability of care while also reducing costs. However, telemedicine does have intrinsic privacy and security risks that all providers must minimize to protect sensitive patient data.
The Inherent Vulnerability of Connectivity
Providers have been eager to adapt to this care delivery method, but many platforms do not meet HIPAA requirements and lack adequate data safeguards. The same connectivity that makes telehealth possible also creates threats to patients. Protecting patient health information (PHI) and providing remote services doesn’t fit together easily.
Any data transferred over the internet runs the risk of interception by threat actors, and healthcare has long been a preferred target for cybercriminals. In 2019, healthcare data breaches cost the industry over $4 billion (2).
This year is no exception with a further increase in ransomware (3) and other attacks that put millions of patients’ records in danger of exposure. These types of events have all happened within typically well-fortified hospital networks.
Connecting with patients via telehealth and transmitting biometric data via remote care devices only furthers these dangers. The biggest risk is that patients lack control of the collection, usage and sharing of their PHI.
For instance, remote monitoring devices built with sensors to detect falls may collect information on other activities patients wish to be kept private—including that their home is unoccupied at certain times and the types of activity they participate in. Even with security measures, any transfer does have a potential for a breach.
How to Prevent Security Risks in Telehealth
More secure telehealth begins by establishing best practices. Because of the sensitive information healthcare organizations possess, providers and the vendors they choose to work with must focus on core elements of data security through related tools and strategies such as:
1. Identity Authentication
Continuous identity authentication ensures authorized individuals have access to data. Identity authentication can be accomplished through a variety of approaches.
Multi-factor authentication, or the requirement of utilizing two pieces of evidence to sign in, is among the most common and has been proven effective in blocking 99.9 percent of all automated cyber-attacks.
Beyond this, users need to develop strong, unique passwords for, not just their telehealth platform accounts, but across their entire online logins and accounts.
2. Improve Telehealth Platform Safety
HIPAA requires that providers integrate encryption and other safeguards into their interactions with patients. However, patients’ devices on the receiving end of care often don’t have these safeguards while some medical devices have been shown to be vulnerable to hackers.
Ensuring the safety of all patient devices in the short term will be impossible. Thus, telehealth platforms must be as secure in themselves as possible. The software needs to be designed in a secure environment and contain numerous ways of establishing secure channels between patients and providers.
3. Investing in Patient Education
Outside of telehealth, cybersecurity ultimately relies on the end-user. As hackers continuously exploit new vulnerabilities, developers are in a constant race to keep up with new threats. Cybersecurity is only as strong as its weakest link. Secure telehealth apps must be complemented by other measures.
For this reason, healthcare providers should educate patients about cybersecurity and the steps they should take to improve the overall safety of their interactions online by:
● Educating patients about the telehealth security threats;
● Using a VPN both during telehealth services and for general device usage;
● Frequently updating all apps and operating systems, not just telehealth platforms;
● Enabling anti-malware and virus scans to run at all times;
● Restricting app permissions to what’s necessary for app functionality only; and
● Recognizing social engineering and other types of cyber-attacks.
How to Minimize Telehealth Security Risks
The one word providers must focus on when implementing telehealth is encryption. It needs to be everywhere. Since data is vulnerable in all stages of its life cycle, including during storage, transmission and access, encryption must be built into every step of this process.
Concerns about the privacy and security of these systems should not adversely affect people’s trust in telehealth. The benefits outweigh the risks. But providers must embrace more rigorous standards and minimize threats to ensure telehealth can deliver on its promises and live up to its potential.
– Microsoft released the public preview of Azure IoT
Connector for FHIR (Fast Healthcare Interoperability Resources), the latest
update to the Microsoft Cloud for Healthcare.
– The Azure IoT Connector for FHIR makes it easy for
health developers to set up a pipeline to manage protected health information
(PHI) from IoT devices and enable care teams to view patient data in context
with clinical records in FHIR.
This week, Microsoft released the preview of Azure
IoT Connector for FHIR—a fully managed feature of the Azure API for FHIR.
The connector empowers health teams with the technology for a scalable
end-to-end pipeline to ingest, transform, and manage Protected Health
Information (PHI) data from devices using the security of FHIR APIs.
and remote monitoring. It’s long been talked about in the delivery of
healthcare, and while some areas of health have created targeted use cases in
the last few years, the availability of scalable telehealth platforms that can
span multiple devices and schemas has been a barrier. Yet in a matter of
months, COVID-19 has accelerated the discussion. There is an urgent need for
care teams to find secure and scalable ways to deliver remote monitoring
platforms and to extend their services to patients in the home environment.
Unlike other services that can use generic video services
and data transfer in virtual settings, telehealth visits and remote monitoring
in healthcare require data pipelines that can securely manage Protected Health
Information (PHI). To be truly effective, they must also be designed for
interoperability with existing health software like electronic medical record
platforms. When it comes to remote monitoring scenarios, privacy, security, and
trusted data exchanges are must-haves. Microsoft is actively investing in
FHIR-based health technology like the Azure IoT Connector for FHIR to ensure
health customers have an ecosystem they trust.
Azure IoT Connector for FHIR Key Features
With the Azure IoT Connector for FHIR available as a feature
on Microsoft’s cloud-based FHIR service, it’s now quick and easy for health
developers to set up an ingestion pipeline, designed for security to manage PHI
from IoT devices. The Azure IoT Connector for FHIR focuses on biometric data at
the ingestion layer, which means it can connect at the device-to-cloud or cloud-to-cloud
workstreams. Health data can be sent to Event Hub, Azure IoT Hub, or Azure IoT
Central, and is converted to FHIR resources, which enables care teams to view
patient data captured from IoT devices in context with clinical records in
Key features of the Azure IoT Connector for FHIR include:
– Conversion of biometric data (such as blood glucose, heart
rate, or pulse ox) from connected devices into FHIR resources.
– Scalability and real-time data processing.
– Seamless integration with Azure IoT solutions and Azure
– Role-based Access Control (RBAC) allows for managing
access to device data at scale in Azure API for FHIR.
– Audit log tracking for data flow.
– Helps with compliance in the cloud: ISO 27001:2013 certified supports HIPAA and GDPR, and built on the HITRUST certified Azure platform.
Microsoft customers are already ushering in the next generation of healthcare
Some of the healthcare organizations who are embracing the technology include:
– Humana will accelerate remote monitoring programs for
patients living with chronic conditions at its senior-focused primary care
subsidiary, Conviva Care Centers.
– Sensoria is enabling secure data exchange from its Motus
Smart remote patient monitoring device, allowing clinicians to see real-time
data and proactively reach out to patients to manage care.
– Centene is managing personal biometric data and will
explore near-real-time monitoring and alerting as part of its overall priority
on improving the health of its members.